Morgan Stanley’s Amplify Treatments, Testing and Advancements ETF GERM Stock Holding History

Morgan Stanley’s Portfolio GERM Stock Details GERM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-4	Closed	-$88	–	8105
2023 Q4	$88	Buy	4 +3	+300%	+$52	﹤0.01%	7504
2023 Q3	$33	Buy	+1	New	+$20	﹤0.01%	7507
2022 Q3	–	Sell	-185	Closed	-$4K	–	7978
2022 Q2	$4K	Hold	185	–	–	﹤0.01%	7475
2022 Q1	$5K	Sell	185 -90	-33%	-$2.54K	﹤0.01%	7600
2021 Q4	$10K	Buy	275 +90	+49%	+$3.37K	﹤0.01%	7474
2021 Q3	$8K	Sell	185 -176	-49%	-$7.43K	﹤0.01%	7406
2021 Q2	$14K	Buy	361 +176	+95%	+$6.57K	﹤0.01%	7142
2021 Q1	$7K	Hold	185	–	–	﹤0.01%	7043
2020 Q4	$6K	Buy	+185	New	+$5.63K	﹤0.01%	6754

Other funds holding GERM

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

CHC

City Holding Co Charleston, West Virginia $884M AUM 27.52% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

TAM

Tucker Asset Management Littleton, Colorado $343M AUM 17.55% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Morgan Stanley's GERM Position: Q1 2024 in Review

Morgan Stanley sold out of Amplify Treatments, Testing and Advancements ETF (GERM) in Q1 2024, closing a stake of 4 shares — an estimated $88 sold.

Morgan Stanley first reported a position in GERM in Q4 2020 and held it in 9 quarters. The position peaked at $14K in Q2 2021. 11 funds tracked by Wall St. Rank hold GERM as of Q1 2024.

Morgan Stanley reported no remaining Amplify Treatments, Testing and Advancements ETF position as of Q1 2024 after selling out during the quarter.
Morgan Stanley sold 4 Amplify Treatments, Testing and Advancements ETF shares in Q1 2024, an estimated $88.
Morgan Stanley first reported a position in Amplify Treatments, Testing and Advancements ETF in Q4 2020 and held it in 9 quarters.
Morgan Stanley's Amplify Treatments, Testing and Advancements ETF position peaked at $14K in Q2 2021.
11 funds tracked by Wall St. Rank held Amplify Treatments, Testing and Advancements ETF as of Q1 2024.

Based on Morgan Stanley's 13F filing for Q1 2024, filed 15 May 2024.